Banks borrow only Rs 2,000 crore on Day 1 of RBI's Rs 50,000 crore liquidity facility for MFs: Report

Industry officials are concerned banks may be unwilling to accept the majority of the low-rated securities as collateral

April 29, 2020 / 10:56 AM IST

Banks on April 28 borrowed only Rs 2,000 crore under the Reserve Bank of India’s (RBI) special liquidity window for mutual funds (MF). The Rs 50,000 crore facility, open until May 11, is aimed at easing the liquidity pressure on funds.

Under the facility, banks can submit bids to avail funding from Monday through Friday, “but the response so far has been poor,” Marzban Irani, CIO-Fixed Income, LIC MF told the Hindu BusinessLine.

The reason why banks are cautious in availing this facility is that they prefer 'AAA'-rated debt instruments or at best  'AA'-rated instruments of microfinance institutions (MFIs), housing finance companies (HFCs) and non-banking finance companies (NBFCs). But there is not much interest in instruments with lower ratings.

Follow our LIVE Updates on the coronavirus pandemic here

Many fund houses have already offloaded high rated papers to ease pressure at the onset of the coronavirus and the ongoing economic slowdown. Banks prefer to stay away from credit-risk in case the papers have been downgraded.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

To avail the Rs 50,000 crore liquidity window till May 11, set up for the mutual fund (MF) sector by the RBI, funds will be allowed to borrow against investment-grade credit risk schemes.

Industry officials, however, are concerned this may not be enough as banks may be unwilling to accept the majority of the low-rated securities as collateral.

RBI’s liquidity window came after Franklin Templeton had closed six funds citing financial crunch due to the COVID-19 situation.

“I don’t see banks taking lower-rated corporate debt as collateral, which has been lacking in liquidity. If we see heavy redemption in schemes which carry large exposure to lower-rated corporate debt, liquidity will remain a problem,” Arvind Chari, head of fixed income, Quantum Advisors, told ET.

Follow our full COVID-19 coverage here
Moneycontrol News
first published: Apr 29, 2020 10:53 am

stay updated

Get Daily News on your Browser
Sections